On 21 March 2018, orphan designation (EU/3/18/1995) was granted by the European Commission to Loxo Oncology Limited, United Kingdom, for larotrectinib for the treatment of salivary gland cancer.
The sponsorship was transferred to Bayer AG - Germany, in June 2018.
|Disease / condition||
Treatment of salivary gland cancer
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.